Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

her2-3

lidERA: giredestrant efficacy by menopausal status in ER+/HER2- breast cancer
4:24
lidERA: giredestrant efficacy by menopausal status in ER+/HER2- breast cancer
Peter Schmid • 3 Jun 2026
Guideline-based sequencing in metastatic HER2-positive breast cancer
1:10
Guideline-based sequencing in metastatic HER2-positive breast cancer
Azka Ali • 30 Jan 2026
Selecting patients with breast cancer for neratinib after neoadjuvant HER2 therapy
2:02
Selecting patients with breast cancer for neratinib after neoadjuvant HER2 therapy
Rupert Bartsch • 28 Jan 2026
Real-world safety of extended adjuvant neratinib: interim NERLYFE data
2:30
Real-world safety of extended adjuvant neratinib: interim NERLYFE data
Rupert Bartsch • 28 Jan 2026
Clinical challenges in managing CNS metastases in HER2+ breast cancer
3:04
Clinical challenges in managing CNS metastases in HER2+ breast cancer
Rupert Bartsch • 28 Jan 2026
TUXEDO-3: HER3-DXd after T-DXd in HER2+ breast cancer with CNS involvement
3:00
TUXEDO-3: HER3-DXd after T-DXd in HER2+ breast cancer with CNS involvement
Rupert Bartsch • 28 Jan 2026
I-SPY 2 EOP: neoadjuvant vepdegestrant combinations in HR+ breast cancer
5:07
I-SPY 2 EOP: neoadjuvant vepdegestrant combinations in HR+ breast cancer
Jo Chien • 19 Jan 2026
ctDNA biomarkers with vepdegestrant in ER+/HER2- advanced breast cancer
3:03
ctDNA biomarkers with vepdegestrant in ER+/HER2- advanced breast cancer
Seth Wander • 19 Jan 2026
How can we move beyond endocrine therapy in HR+/HER2- breast cancer?
4:44
How can we move beyond endocrine therapy in HR+/HER2- breast cancer?
Sung-Bae Kim • 12 Jan 2026
Real-world outcomes with 1L regimens in HER2+ metastatic breast cancer
2:23
Real-world outcomes with 1L regimens in HER2+ metastatic breast cancer
Azka Ali • 23 Dec 2025
Assessing risk and treatment options in HR+/HER2- breast cancer
1:31
Assessing risk and treatment options in HR+/HER2- breast cancer
Nicholas McAndrew • 20 Nov 2025
EMERALD: eribulin plus dual HER2 blockade in first-line HER2+ breast cancer
1:20
EMERALD: eribulin plus dual HER2 blockade in first-line HER2+ breast cancer
Shigehira Saji • 21 Oct 2025
MonarchE: Ki-67 dynamics and prognostic value in HR+/HER2- breast cancer
1:23
MonarchE: Ki-67 dynamics and prognostic value in HR+/HER2- breast cancer
Shigehira Saji • 21 Oct 2025
CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
0:48
CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
Paola Zagami • 30 Jun 2025
VERITAC-2: vepdegestrant versus fulvestrant in ER+/HER2- breast cancer
1:35
VERITAC-2: vepdegestrant versus fulvestrant in ER+/HER2- breast cancer
Erika Hamilton • 12 Jun 2025
Analyzing the findings of the SERENA-6 trial and its implications in the clinic
1:52
Analyzing the findings of the SERENA-6 trial and its implications in the clinic
Michael Gnant • 6 Jun 2025
The content of VJOncology is intended for healthcare professionals